Component: (Network and Table)
Network
00500 - Statement - Consolidated Statements of Cash Flows
(http://www.egalet.com/role/StatementConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001586105 (http://www.sec.gov/CIK)
Consolidated Statements of Cash FlowsPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Consolidated Statements of Cash Flows
 
 
 
Operating activities:
 
 
 
Net loss
(90,632,000) 
(57,933,000) 
(43,214,000) 
Adjustment to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
4,118,000  
3,014,000  
641,000  
Change in fair value of derivative liability
(644,000) 
(260,000) 
 
Stock based compensation expense
6,323,000  
5,199,000  
8,518,000  
Noncash interest and amortization of debt discount
5,911,000  
3,957,000  
6,987,000  
Amortization of premium on marketable securities
607,000  
829,000  
 
Deferred income taxes
(1,061,000) 
(718,000) 
6,000  
Loss on extinguishment of debt
800,000  
  
Changes in assets and liabilities:
 
 
 
Related party receivable
57,000  
563,000  
(744,000) 
Accounts receivable
(813,000) 
(295,000) 
 
Inventory
137,000  
1,571,000  
 
Prepaid expenses and other current assets
(1,243,000) 
(631,000) 
(540,000) 
Other receivables
28,000  
(144,000) 
(883,000) 
Deposits and other assets
1,481,000  
(2,050,000) 
 
Accounts payable
(2,945,000) 
1,147,000  
3,268,000  
Accrued expenses
10,553,000  
5,123,000  
1,412,000  
Deferred revenue
(6,153,000) 
1,485,000  
(557,000) 
Other current liabilities
(187,000) 
116,000  
32,000  
Other liabilities
796,000  
121,000  
 
Net cash used in operating activities
(72,867,000) 
 
(38,906,000) 
 
(25,074,000) 
 
Investing activities:
 
 
 
Payments for purchase of property and equipment
(7,237,000) 
(2,747,000) 
(2,889,000) 
Deposits for purchases of property and equipment
 
(1,223,000) 
(854,000) 
Purchases of investments
(59,545,000) 
(110,216,000) 
 
Sales of investments
14,370,000  
3,400,000  
 
Maturity of investments
101,277,000  
6,799,000  
 
Purchase of SPRIX Nasal Spray
 
(8,128,000) 
 
License of OXAYDO
 
(7,672,000) 
 
Net cash (used in) provided by investing activities
48,865,000  
 
(119,787,000) 
 
(3,743,000) 
 
Financing activities:
 
 
 
Net proceeds from issuance of common stock
272,000  
80,896,000  
66,982,000  
Payments on borrowings
(15,856,000) 
  
Net proceeds from debt and royalty rights
37,231,000  
71,397,000  
 
Net cash provided by financing activities
21,647,000  
 
152,293,000  
 
66,982,000  
 
Effect of foreign currency translation on cash and cash equivalents
45,000  
327,000  
(1,127,000) 
Net increase (decrease) in cash and cash equivalents
(2,310,000) 
 
(6,073,000) 
 
37,038,000  
 
Cash at beginning of period
46,665,000  
52,738,000  
15,700,000  
Cash at end of period
44,355,000  
 
46,665,000  
 
52,738,000  
 
Supplemental disclosure of cash flow information:
 
 
 
Non-cash purchases of property and equipment
 
2,084,000  
 
Non-cash financing activities:
 
 
 
Conversion of convertible preferred stock
  
14,957,000  
Issuance of warrants
 
329,000  
 
Cash interest payments
4,712,000  
3,461,000  
 
Conversion of related party convertible debt
  
24,713,000